Gaurav Shah, Chief Executive Officer of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), filed a Form 4 on August 17, 2026, disclosing the sale of 2,837 shares of common stock on August 13, 2026, to cover tax withholding obligations related to the vesting of restricted stock units.

Key Highlights

  • Transaction date: 2,837 shares of common stock were disposed of on August 13, 2026, at a price of $3.381 per share.
  • Purpose stated: According to the filing, the shares were sold "in order to pay tax withholding obligations in connection with the vesting of RSUs."
  • Transaction code: The disposal was coded "S" (sale) under Instruction 8.
  • Direct holdings after transaction: Shah directly owned 1,058,887 shares following the reported transaction, including RSUs that convert to common stock on a one-for-one basis.
  • Indirect holdings: The filing also reports 207,897 shares held indirectly by spouse and 198,341 shares held indirectly by the Gaurav D. Shah Irrevocable Trust.
  • Signing authority: The form was signed by Martin Wilson as attorney-in-fact for Gaurav Shah on August 17, 2026.

Rocket Pharmaceuticals CEO RSU Vesting Triggers Tax-Related Share Sale

According to the Form 4 filed with the SEC, Gaurav Shah, who serves as CEO of Rocket Pharmaceuticals, Inc., disposed of 2,837 shares of common stock on August 13, 2026. The filing states the shares were sold at $3.381 each and identifies the purpose as covering tax withholding obligations arising from the vesting of restricted stock units (RSUs). The transaction was coded "S" and classified as a disposal ("D") under the applicable instructions.

Following the reported transaction, the filing discloses that Shah directly held 1,058,887 shares, a figure the filing notes includes RSUs that convert to common stock on a one-for-one basis. In addition to direct holdings, the filing reports two categories of indirect beneficial ownership: 207,897 shares held by spouse and 198,341 shares held by the Gaurav D. Shah Irrevocable Trust. No derivative securities transactions were reported in Table II of the filing.

The Form 4 was filed on August 17, 2026, with August 13, 2026, cited as the date of the earliest transaction. The document was submitted by Martin Wilson as attorney-in-fact for Gaurav Shah. No amendment date was provided, indicating this is an original filing rather than a revision to a previously submitted form.

What Was Disclosed

The filing reports a single disposal of 2,837 common shares by the CEO of Rocket Pharmaceuticals at $3.381 per share on August 13, 2026, for the stated purpose of satisfying tax withholding on vested RSUs, with total direct beneficial ownership of 1,058,887 shares reported after the transaction.